Located in NES-ZIONA, Israel, PROLOR Biotech is a clinical stage biopharmaceutical company that applies unique technologies to approved therapeutic proteins that generate billions of dollars in annual sales. Known for its patented CTP technology, PROLR Biotech has become a leader in their field. Today, the company took a major step towards prominence with the announcement of relation and expansion of their corporate offices and their R&D facility.

The move, which is expected to be completed by April 15, will allow PROLOR Biotech to have an upgraded R&D facility that encompasses 10,000 feet of leased space. This larger building will allow the company to extend its power across the sector.

The expanded R&D facility includes clean rooms for GMP-grade production of therapeutic drug candidates, allowing PROLOR to produce a variety of therapeutic proteins for research and development applications with better control, lower costs and faster production cycles.

One of the leaders at PROLOR Biotech is Shai Novik whom serves as the company’s President. When asked what this new facility will mean to the future of the company, Novik was quoted as saying, “This new facility makes it possible for us to strengthen our capabilities across the board, and we intend to leverage it fully to help accomplish our stated milestones.”

To learn more about this up-and-coming company, visit their website at: www.prolor-biotech.com